Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …

This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …

Abstract Machine Learning is one of the importantareas for modeling the data and itcan be
saidthat this is the core part of the field of Data Science. Supervised Machine Learning (SML)…

Background The literature on first generation COVID-19 vaccines show they were less effective
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …

Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…

Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …